Skip to content

Serum Bile Acid Profiles in Patients With Intrahepatic Cholestasis of Pregnancy

Serum Bile Acid Profiles in Patients With Intrahepatic Cholestasis of Pregnancy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07428226
Acronym
BAPP
Enrollment
74
Registered
2026-02-23
Start date
2024-07-01
Completion date
2027-12-31
Last updated
2026-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic Cholestasis of Pregnancy

Keywords

Intrahepatic Cholestasis of pregnancy, Bile acid profile

Brief summary

The goal of this observational study is to learn if analyzing bile acid patterns can help predict dangerous complications in pregnant women with intrahepatic cholestasis of pregnancy (ICP), a liver condition that can affect the baby. The main questions it aims to answer are: * Can measuring specific types of bile acids (particularly taurine-conjugated versus glycine-conjugated bile acids) in the mother's and baby's blood help predict the risk of stillbirth and other complications? * Do these bile acid patterns activate specific receptors (TGR5) that might contribute to immune problems or heart rhythm abnormalities in the baby? * How do bile acid patterns in the mother's stool relate to her gut bacteria and the severity of ICP? * Can heart rate monitoring (CTG) combined with bile acid measurements better identify high-risk pregnancies? ICP is a pregnancy-related liver condition that causes bile acids to build up in the mother's bloodstream. This can lead to serious risks for the baby, including an increased chance of stillbirth, premature birth, and heart rhythm problems. Current monitoring methods (such as heart rate monitoring and ultrasound) often don't show warning signs before complications occur. Participants will: * Provide blood samples at each routine bile acid check during pregnancy and at delivery * Provide stool samples for analyzing gut bacteria and bile acids * Have their baby's umbilical cord blood collected at birth for bile acid analysis * Undergo standard heart rate monitoring (CTG) of the baby * Have ultrasound examination of the baby's heart (echocardiography) The study will compare three groups: pregnant women with ICP, healthy pregnant women, and healthy non-pregnant women. The researchers hope this information will help doctors better predict which pregnancies need more intensive monitoring and potentially prevent stillbirths and other complications in women with ICP.

Interventions

None listed

Sponsors

Jena University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

Group I: * Minimum age of 18 years * Written informed consent * Pregnant patients with suspected ICP * Pregnant patients with confirmed ICP * Pregnant patients with elevated total bile acids (\>14 µmol/ml) * Pregnant patients with elevated liver enzymes * Pregnant patients that suffer from itching with elevated transaminases Inclusion Criteria Group II: * Minimum age of 18 years * Confirmed pregnancy * Written informed consent * Generally considered healthy in common usage (corresponding to ASA II of the American Society of Anesthesiologists classification) Inclusion Criteria Group III: * Minimum age of 18 years * Female gender * Pregnancy excluded * Written informed consent * Generally considered healthy in common usage (corresponding to ASA II of the American Society of Anesthesiologists classification)

Exclusion criteria

Group II and III: * Age \<18 years * Inability to provide informed consent * Signs of an acute illness (for control groups II and III) * Known liver, biliary, or pancreatic diseases (for control groups II and III) * ICP in personal or family medical history (for control groups II and III)

Design outcomes

Primary

MeasureTime frameDescription
bile acid profilePregnant women: from inclusion to delivery; Non-pregnant female volunteers: at inclusionQualitative and quantitative bile acid profile in serum of mother and infant (umbilical cord blood)

Secondary

MeasureTime frameDescription
TGR-5 activityPregnant women: from inclusion to delivery; Non-pregnant female volunteers: at inclusionTGR5 activation by immunosuppressive bile acids calculated according to published protocols (Leonhardt et al. 2021)
bile acid profile in stoolPregnant women: from inclusion to delivery; Non-pregnant female volunteers: at inclusionThe bile acid profile in stool is an exploratory outcome measure that examines the composition and concentration of various bile acids in stool samples.
materno-fetal bile acid transfer rate (bile acid profile)Pregnant women: from inclusion to delivery; Non-pregnant female volunteers: at inclusionThe maternal-fetal bile acid transfer rate describes the extent and efficiency with which bile acids pass from the mother through the placenta into the fetal circulation (placental permeability).

Countries

Germany

Contacts

CONTACTSilke Große, Dr. rer. nat.
silke.grosse@med.uni-jena.de+493641 9-329293
CONTACTJanine Zöllkau, Dr. med.
janine.zoellkau@med.uni-jena.de
STUDY_CHAIRTanja Groten, Prof. Dr. med.

University Hospital Jena

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026